Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應用
N-Boc Palbociclib is a protected Palbociclib (P139900),(also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
參考文獻
Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);
滬ICP備17019645號
400-821-0725
